Investigating the Pharmacokinetics of Natural Products: Challenges and Advances in Bioavailability

Takashi Asano^*
*Correspondence: Takashi Asano, Department of Biological Sciences, Chukyo University, 101-2 Yagotohonmachi, Showa Ward, Nagoya, Aichi 466-0825, Japan, Email:

Introduction

The therapeutic potential of natural products, including compounds derived from plants, fungi, and marine organisms, has long been recognized in traditional medicine and modern pharmacology. However, the successful clinical application of these natural products is often hindered by issues related to their pharmacokinetics, particularly bioavailability. Bioavailability refers to the proportion of an administered dose of a compound that reaches the systemic circulation in its active form, and it is a critical determinant of the compound's therapeutic efficacy. This review explores the challenges and recent advances in investigating and improving the pharmacokinetics and bioavailability of natural products. We discuss the key factors affecting bioavailability, current methodologies for pharmacokinetic evaluation, and innovative strategies that have been developed to enhance the oral bioavailability of bioactive compounds. Furthermore, we highlight emerging technologies and future directions that hold promise for improving the clinical translation of natural products.

Natural products have provided a significant source of therapeutic agents for centuries, with many currently used drugs originating from plant, microbial, and marine sources. These bioactive compounds are typically secondary metabolites, such as alkaloids, terpenoids, flavonoids, and glycosides, which exhibit a wide range of pharmacological activities, including anti-inflammatory, anticancer, antimicrobial, and antioxidant properties. Despite their extensive biological activities, the clinical application of these compounds is often limited by their pharmacokinetic properties, particularly their bioavailability.

Pharmacokinetics involves the study of the absorption, distribution, metabolism, and excretion of a compound. Bioavailability, which refers to the fraction of an administered drug or natural product that enters the systemic circulation, is a key component of pharmacokinetics. Poor bioavailability can result from factors such as low solubility, poor absorption in the gastrointestinal tract, extensive first-pass metabolism in the liver, and rapid elimination from the body. Consequently, understanding the pharmacokinetics of natural products and improving their bioavailability is essential for optimizing their therapeutic potential.

This article aims to provide an overview of the challenges and recent advancements in the pharmacokinetics and bioavailability of natural products. We will explore the factors that influence bioavailability, review current approaches to pharmacokinetic analysis, and examine strategies to improve the bioavailability of natural compounds for therapeutic use. One of the primary challenges in studying the pharmacokinetics of natural products is their chemical complexity. Unlike synthetic drugs, which are often single, well-defined compounds, natural products are typically mixtures of multiple active compounds, each with its own pharmacokinetic profile. This diversity complicates the isolation and quantification of individual components, making it difficult to accurately assess their pharmacokinetics.

Description

In addition, the composition of natural products can vary depending on factors such as plant species, geographical location, cultivation methods, and environmental conditions. This variability poses challenges for ensuring consistency in bioavailability studies and pharmacokinetic predictions. Many natural products exhibit poor water solubility and low permeability across biological membranes, both of which significantly limit their bioavailability. Poor solubility in the gastrointestinal tract can result in insufficient absorption into the bloodstream, while low permeability across the intestinal epithelium further exacerbates this issue. This is particularly true for large, hydrophobic compounds, such as polyphenols, alkaloids, and flavonoids, which are common in natural products.

First-pass metabolism refers to the rapid metabolism of orally administered compounds by the liver before they reach systemic circulation. Many natural products are substrates for hepatic enzymes, such as cytochrome P450 isoforms, which can metabolize the compound to inactive or less active forms. This process further reduces the bioavailability of many natural products, particularly those that are extensively metabolized.

Another challenge is the inter-individual variability in the pharmacokinetics of natural products. Genetic differences, diet, gut microbiota composition, and co-administration with other drugs can all influence the absorption, distribution, and metabolism of natural products. This variability complicates the prediction of their pharmacokinetic behavior in different populations, including patients with co-morbidities or those taking polypharmacy [1-3]. The lack of standardized methodologies for evaluating the pharmacokinetics of natural products further complicates their clinical application. Traditional pharmacokinetic studies typically use synthetic drugs with well-defined chemical structures, allowing for the application of standardized protocols for ADME evaluation. However, the diverse nature of natural products, their mixture of active compounds, and the need for high-throughput screening pose significant challenges in establishing reliable and reproducible methodologies for assessing their pharmacokinetics.

Recent advancements in analytical techniques, such as high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy, have significantly improved the ability to identify and quantify the individual components of natural products. These techniques allow for the precise determination of the pharmacokinetic profiles of each active compound in a natural product mixture, leading to a better understanding of their absorption, metabolism, and elimination pathways.

Moreover, in vivo imaging techniques, such as positron emission tomography and magnetic resonance imaging, are being explored to visualize the distribution and metabolism of natural products within the body in realtime, further improving pharmacokinetic studies. Nanotechnology has emerged as a promising approach to improve the bioavailability of natural products. Nanoparticles, liposomes, and solid lipid nanoparticles can be used to encapsulate bioactive compounds, enhancing their solubility, stability, and permeability. These drug delivery systems can protect natural products from degradation, promote sustained release, and facilitate targeted delivery to specific tissues or organs, improving their therapeutic efficacy.

For example, curcumin, a polyphenolic compound derived from Curcuma longa, has poor bioavailability due to its low solubility and rapid metabolism. Nanocarrier systems, such as curcumin-loaded liposomes or nanoparticles, have been developed to improve its solubility and bioavailability, leading to enhanced therapeutic effects in clinical studies. Pharmacokinetic modeling and simulation techniques, such as compartmental modeling and physiologically based pharmacokinetic modeling, are increasingly being used to predict the absorption, distribution, metabolism, and excretion of natural products. These computational models can be used to simulate the pharmacokinetic profiles of natural compounds based on their chemical properties, allowing for the optimization of dosing regimens and the identification of potential interactions with other drugs [4,5].

PBPK models, in particular, have shown promise in predicting the effect of factors such as drug-drug interactions, genetic variability, and disease states on the pharmacokinetics of natural products. Emerging evidence suggests that the gut microbiota plays a crucial role in the bioavailability of natural products. The microbiome can influence the absorption, metabolism, and bioactivation of many natural compounds. For example, the conversion of polyphenols and flavonoids into their active metabolites often depends on the activity of gut microbial enzymes. As such, understanding the interactions between natural products and the gut microbiota is crucial for improving their bioavailability. Researchers are exploring prebiotics, probiotics, and dietary interventions to modulate the gut microbiota and enhance the bioavailability of natural products. Chemical modification of natural products, including the synthesis of analogs or derivatives, is another strategy for improving bioavailability. By modifying the chemical structure of natural compounds, researchers can enhance their solubility, stability, and resistance to first-pass metabolism, thereby improving their pharmacokinetic properties.

For instance, resveratrol, a polyphenol found in grapes and berries, is poorly absorbed and rapidly metabolized in the liver. Structural modifications of resveratrol, such as the development of resveratrol derivatives or prodrugs, have been explored to improve its bioavailability and therapeutic efficacy.

Conclusion

The pharmacokinetics and bioavailability of natural products present significant challenges for their clinical application. Factors such as chemical complexity, poor solubility, first-pass metabolism, and inter-individual variability complicate the successful use of natural products as therapeutic agents. However, recent advances in analytical techniques, nanotechnology, drug delivery systems, and pharmacokinetic modeling offer promising strategies to enhance the bioavailability of natural compounds. Additionally,understanding the role of gut microbiota and exploring chemical modifications of natural products may further improve their therapeutic potential.

As research continues to evolve, it is likely that the combination of these innovative approaches will lead to the successful translation of natural products from traditional remedies to modern pharmacological therapies. Future studies should focus on developing standardized methodologies, refining drug delivery systems, and better understanding the pharmacokinetic profiles of natural products to unlock their full clinical potential.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Pereira, David M., Joana Faria, Luís Gaspar and Patrícia Valentão, et al. "Boerhaavia diffusa: Metabolite profiling of a medicinal plant from Nyctaginaceae." Food Chem Toxicol 47 (2009): 2142-2149.

Google Scholar, Crossref, Indexed at

2. Wybenga, D. R., V. J. Pileggi, Ph H. Dirstine and John Di Giorgio. "Direct manual determination of serum total cholesterol with a single stable reagent." Clin Chem 16 (1970): 980-984.

Google Scholar, Crossref, Indexed at

3. Tang, Jinhua, Haidong Yan and Shougang Zhuang. "Inflammation and oxidative stress in obesity‐related glomerulopathy." Int J Nephrol 2012 (2012): 608397.

Google Scholar, Crossref, Indexed at

4. Huat, Tee Jong, Judith Camats-Perna, Estella A. Newcombe and Nicholas Valmas, et al. "Metal toxicity links to Alzheimer's disease and neuroinflammation." J Mol Biol 431 (2019): 1843-1868.

Google Scholar, Crossref, Indexed at

5. March, Raymond E., Xiu‐Sheng Miao and Chris D. Metcalfe. "A fragmentation study of a flavone triglycoside, kaempferol‐3‐O‐robinoside‐7‐O‐rhamnoside." Rapid Commun Mass Spectrom 18 (2004): 931-934.

Google Scholar, Crossref, Indexed at